CYP2D6-guided opioid therapy for adults with cancer pain: A randomized implementation clinical trial.

ABSTRACT:

Introduction

The CYP2D6 enzyme metabolizes opioids commonly prescribed for cancer-related pain, and CYP2D6 polymorphisms may contribute to variability in opioid response. We evaluated the feasibility of implementing CYP2D6-guided opioid prescribing for patients with cancer and reported pilot outcome data.

Methods

Adult patients from two cancer centers were prospectively enrolled into a hybrid implementation-effectiveness clinical trial and randomized to CYP2D6-genotype-guided opioid selection, with clinical recommendations, or usual care. Implementation metrics, including provider response, medication changes consistent with recommendations, and patient-reported pain and symptom scores at baseline and up to 8 weeks, were assessed.

Results

Most (87/114, 76%) patients a

SUBMITTER: Mosley SA 

PROVIDER: S-EPMC10840965 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature